Posted in | News | Imaging | Medical Optics

New Way to Diagnose Skin Cancer

Non-melanoma skin cancer, which includes basal cell carcinoma and squamous cell carcinoma, accounts for 90% of all skin malignancies and represents a significant health problem worldwide. In the UK and the USA respectively, there are approximately 100,000 and 1,000,000 new cases reported every year. Although a number of novel imaging techniques have become available, there is still no gold standard for skin cancer imaging.

Most incidences of skin cancer are diagnosed based on clinical history and visual inspection by a clinician. In many cases the diagnosis still remains unclear and a biopsy is required for confirmation. A non-invasive method of assessment would be desirable.

Scientists from Sweden and the UK studied the application of both a time-resolved fluorescence spectrofluorometer and a compact instrument combining steady-state spectroscopy of diffuse reflected light and fluorescence to investigate the clinical diagnostic potential of autofluorescence and reflectance measurements of tissue. A total of 25 patients at Lund University Hospital were measured prior to surgical excision of the investigated region. The experiments revealed clear differences between healthy and diseased tissue both in terms of spectral properties and autofluorescence lifetime (for excitation at 445 nm), indicating the potential of these instruments for clinical diagnostic purposes.

The team lead by Alex J. Thompson and Chris Dunsby from the Imperial College in London (UK) used singular value decomposition to reduce the dimensionality of steady state diffuse reflectance and fluorescence spectra. Linear discriminant analysis was then applied to the measurements of basal cell carcinomas (BCCs) and used to predict the tissue disease state with a leave-one-out methodology. Leave-one-out cross-validation works by using a single observation from the original sample as the validation data, and the remaining observations as the training data. Each observation in the sample is used once as the validation data.

With the help of this approach, the researchers were able to correctly diagnose 87% of the BCCs. When using 445 nm excitation they observed a decrease in the spectrally averaged fluorescence lifetime between normal tissue and BCC lesions with a mean value of 886 ps. Furthermore, the scientists found the fluorescence lifetime for BCCs to be lower than that of the surrounding healthy tissue in all cases. A statistical analysis of the data revealed that this decrease was significant.

Future work will involve increasing the number of lesions investigated such that it is possible to draw statistically significant conclusions for several more individual sub-classes of skin cancer such as squamous cell carcinomas and malignant melanomas. (Text by K. Maedefessel-Herrmann)

A. J. Thompson et al., J. Biophotonics 5(3), 240-254 (2012); http://dx.doi.org/10.1002/jbio.201100126

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    John Wiley and Sons - Scientific Publishers. (2019, February 28). New Way to Diagnose Skin Cancer. AZoOptics. Retrieved on June 16, 2024 from https://www.azooptics.com/News.aspx?newsID=15211.

  • MLA

    John Wiley and Sons - Scientific Publishers. "New Way to Diagnose Skin Cancer". AZoOptics. 16 June 2024. <https://www.azooptics.com/News.aspx?newsID=15211>.

  • Chicago

    John Wiley and Sons - Scientific Publishers. "New Way to Diagnose Skin Cancer". AZoOptics. https://www.azooptics.com/News.aspx?newsID=15211. (accessed June 16, 2024).

  • Harvard

    John Wiley and Sons - Scientific Publishers. 2019. New Way to Diagnose Skin Cancer. AZoOptics, viewed 16 June 2024, https://www.azooptics.com/News.aspx?newsID=15211.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.